Literature DB >> 27286845

Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases.

Hisanori Kinoshita1, Hodaka Yamakado2, Toshiyuki Kitano3, Akihiro Kitamura4, Hirofumi Yamashita4, Masakazu Miyamoto4, Takefumi Hitomi5, Tomohisa Okada6, Yuji Nakamoto6, Nobukatsu Sawamoto4, Akifumi Takaori-Kondo3, Ryosuke Takahashi4.   

Abstract

Neurolymphomatosis (NL) is a rare condition involving the infiltration of lymphoma cells into the peripheral nervous system. NL can be primary or secondary in the setting of an unknown or known hematologic malignancy, respectively. Here, we report five cases in which F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (F-18 FDG-PET/CT) had great value for diagnosing NL. Two cases were rare primary NL, and the other three were secondary NL. Clinical presentations were asymmetric sensorimotor disturbances in the extremities with or without involvement of cranial nerves. Furthermore, all patients experienced spontaneous pain in the face or affected extremities. Cerebrospinal fluid analysis was cytologically negative in two of five cases. Gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) detected abnormalities in the cranial nerves, nerve roots, and cauda equina in all cases except case 1 and the recurrent stage of case 2. F-18 FDG-PET/CT showed clear visualization of almost all the lymphomatous involvement of peripheral nerves and other tissues in all patients. Furthermore, F-18 FDG-PET/CT detected abnormalities including asymptomatic lesions that were not detected with MRI, and also identified the appropriate lesion for diagnostic biopsy. However, as in case 3, the lesions in the left oculomotor nerve and the cauda equina were detected only with Gd-enhanced MRI, which has superior spatial resolution. In conclusion, F-18 FDG-PET/CT is a sensitive modality that can suggest the presence of malignancy and identify appropriate places for diagnostic biopsies. It is especially useful when combined with Gd-enhanced MRI, even in patients with primary NL that is usually difficult to diagnose.

Entities:  

Keywords:  FDG-PET; Lymphoma; MRI; Neurolymphomatosis; Painful neuropathy

Mesh:

Substances:

Year:  2016        PMID: 27286845     DOI: 10.1007/s00415-016-8190-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

1.  Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.

Authors:  Sigal Grisariu; Batia Avni; Tracy T Batchelor; Martin J van den Bent; Felix Bokstein; David Schiff; Outi Kuittinen; Marc C Chamberlain; Patrick Roth; Anatoly Nemets; Edna Shalom; Dina Ben-Yehuda; Tali Siegal
Journal:  Blood       Date:  2010-04-05       Impact factor: 22.113

2.  Clinicopathological features of neuropathy associated with lymphoma.

Authors:  Minoru Tomita; Haruki Koike; Yuichi Kawagashira; Masahiro Iijima; Hiroaki Adachi; Jun Taguchi; Takenori Abe; Kazuya Sako; Yukiko Tsuji; Masanori Nakagawa; Fumio Kanda; Fusako Takeda; Masashiro Sugawara; Itaru Toyoshima; Naoko Asano; Gen Sobue
Journal:  Brain       Date:  2013-08       Impact factor: 13.501

3.  Neurolymphomatosis.

Authors:  Joachim M Baehring; Denise Damek; Emily C Martin; Rebecca A Betensky; Fred H Hochberg
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

Review 4.  Role of functional imaging in the management of lymphoma.

Authors:  Bruce D Cheson
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

5.  Neurolymphomatosis: A report of 2 cases representing opposite ends of the clinical spectrum.

Authors:  Rajat Lahoria; P James B Dyck; William R Macon; Brian A Crum; Robert J Spinner; Kimberly K Amrami; Steven R Zeldenrust; Jennifer A Tracy
Journal:  Muscle Nerve       Date:  2015-05-14       Impact factor: 3.217

Review 6.  Increasing importance of 18F-FDG PET in the diagnosis of neurolymphomatosis.

Authors:  Liesbeth P Salm; Bernies Van der Hiel; Marcel P M Stokkel
Journal:  Nucl Med Commun       Date:  2012-09       Impact factor: 1.690

7.  Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography.

Authors:  Satoshi Nakajima; Tomohisa Okada; Akira Yamamoto; Mitsunori Kanagaki; Yasutaka Fushimi; Tsutomu Okada; Yoshiki Arakawa; Yasushi Takagi; Susumu Miyamoto; Kaori Togashi
Journal:  Clin Imaging       Date:  2014-12-12       Impact factor: 1.605

8.  18F-Florbetapir and 18F-FDG PET/CT in Systemic Immunoglobulin Light Chain Amyloidosis Involving the Peripheral Nerves.

Authors:  Stephen M Broski; Robert J Spinner; Benjamin M Howe; Angela Dispenzieri; Geoffrey B Johnson
Journal:  Clin Nucl Med       Date:  2016-02       Impact factor: 7.794

9.  Neurolymphomatosis mimicking chemotherapy-induced ototoxicity.

Authors:  Robert S Hong; Erika A Woodson; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2009-06       Impact factor: 2.311

10.  Diagnostic Yield of FDG-PET/CT, MRI, and CSF Cytology in Non-Biopsiable Neurolymphomatosis as a Heralding Sign of Recurrent Non-Hodgkin's Lymphoma.

Authors:  Faiq Shaikh; Aubrey C Chan; Omer Awan; Nivedita Jerath; Chandan Reddy; Salman A Khan; Michael M Graham
Journal:  Cureus       Date:  2015-09-09
View more
  3 in total

1.  Neurolymphomatosis: a single-center experience of neuromuscular manifestations, treatments, and outcomes.

Authors:  Jisun Jeong; Sun Woong Kim; Duk Hyun Sung
Journal:  J Neurol       Date:  2020-10-23       Impact factor: 4.849

2.  Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era.

Authors:  Arushi Khurana; Mattia Novo; Grzegorz S Nowakowski; Kay M Ristow; Robert J Spinner; Christopher H Hunt; Rebecca L King; Daniel H Lachance; Thomas M Habermann; Ivana N Micallef; Patrick B Johnston
Journal:  Blood Adv       Date:  2021-03-09

3.  Partial Conduction Block as an Early Nerve Conduction Finding in Neurolymphomatosis.

Authors:  Hyung Jun Park; Ha Young Shin; Se Hoon Kim; Ha Neul Jeong; Young Chul Choi; Bum Chun Suh; Kee Duk Park; Seung Min Kim
Journal:  J Clin Neurol       Date:  2018-01       Impact factor: 3.077

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.